Carlson Caspers represented Teva Pharmaceuticals in its effort to seek FDA permission to market a generic version of Treximet® (sumatriptan and naproxen sodium) before expiration of Pozen’s patents. Our client settled its case, while other litigants that proceeded through trial were found to infringe patents that were further found not invalid.